National Academies Press: OpenBook

Contraceptive Research and Development: Looking to the Future (1996)

Chapter: Appendix F: Committee Biographies

« Previous: Appendix E: Agendas and Participants in Committee Workshops
Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×

F: Committee Biographies

Hedia Belhadj-El Ghouayel, MD, is Technical Officer in the Reproductive Health Branch in the Technical and Evaluation Division, United Nations Population Fund (UNFPA). She obtained her MD from the Faculty of Medicine of Tunis and a specialist degree in endocrinology and metabolic diseases from the Universities of Tunis and Paris. Dr. Belhadj was UNFPA country director for Yemen, Oman, and Djibouti (1991-1993) and program officer for the Arab States and Europe (1989-1991). From 1985 to 1988, Dr. Belhadj was a Tietze Fellow at the Population Council's Center for Biomedical Research, working on clinical studies for development of contraceptive technologies and basic research in reproductive physiology.

Donald D. Brown, MD, is Director of the Department of Embryology, the Carnegie Institute of Washington. He earned his MD from the University of Chicago. Dr. Brown is a Fellow of the American Academy of Arts and Sciences, the American Society of Cell Biology, and the National Academy of Sciences of the United States. He has earned numerous awards, including the Honorary Doctor of Science, University of Cincinnati (1992); the Feodor Lynen award from the University of Miami Winter Symposium (1987); and the Louisa Gross Horwitz Award from Columbia University and the Rosenstiel Award in Basic Biomedical Science from Brandeis University in 1985.

Nancy L. Buc is Partner in the law firm of Buc and Beardsley in Washington, DC, and earned her LLB from the University of Virginia. In 1980-1981 she was Chief Counsel for the United States Food and Drug Administration, prior to

Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×

which she was Partner in the law firm of Weil, Gotshal, and Manges. Her awards include the LLD honoris causa from Brown University (1994), Distinguished Service Award from the Federal Trade Commission (1972), and the Secretary's Special Citation and Award of Merit from the USFDA (1981). Ms. Buc is on the boards of directors of the Alan Guttmacher Institute and Women's Legal Defense Fund and on the editorial boards of the Food Drug and Cosmetic Law Journal and Journal of Products Liability.

Peter F. Carpenter, MBA, is a public policy/public service fellow at the Mission and Values Institute; Adjunct Professor, Department of Epidemiology and Biostatistics, McGill University; and Visiting Scholar, Center for Biomedical Ethics, Stanford University. He is a graduate of Harvard University and received his MBA from the University of Chicago in 1965. From 1976 to 1992, Mr. Carpenter worked for the ALZA Corporation, where he served as president for eight years. He has served on the IOM Committee to Study Decision-Making on Biomedical Innovations, Committee on the Social and Ethical Impact of Advances in Biomedicine, and Committee to Study Medications Development and Research at the National Institute on Drug Abuse.

Willard Cates, Jr., MD, MPH, is Corporate Director of Medical Affairs at Family Health International, prior to which he served as Director, Division of Training, Epidemiology Program Office, Centers for Disease Control; from 1982 to 1991 he served as director of CDC's Division of Sexually Transmitted Diseases and HIV. He earned his MPH and MD at the Yale University School of Medicine. Dr. Cates is a member of the NAS Committee on Population study of Reproductive Health in Developing Countries and has served several Institute of Medicine study committees beginning in 1975. He is a member of the Board of Overseers for the American Journal of Epidemiology, Associate Editor of Sexually Transmitted Diseases, and is on the editorial advisory board for the Journal of Reproductive Health Medicine and Venereology.

Rebecca J. Cook, JD, JSD, is Professor, Faculty of Law, University of Toronto, and Adjunct Associate Professor in the Division of Population and Family Health at the Columbia University School of Public Health. She received her JSD at the Columbia University School of Law and her JD at Georgetown University Law Center. She serves on the editorial advisory boards of Drug Regulation and Reproductive Health , Family Planning Perspectives , Journal of Third World Legal Studies , and Reproductive Health Matters. She is a member of the Scientific and Ethical Review Group of the Human Reproduction Programme of the World Health Organization, International Women's Rights Action Watch, and Profamilia Servicios Legales para Mujeres in Bogotá, Colombia.

Horacio B. Croxatto, MD, is President of the Chilean Institute of Reproductive

Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×

Medicine and Professor of Reproductive Physiology at the Catholic University of Chile. He received his MD at the School of Medicine of the Catholic University of Chile. Dr. Croxatto is a member of several Chilean medical and research societies, the American Society of Reproductive Medicine, and the Society for the Study of Reproduction. He has authored numerous articles in scientific journals and invited book chapters on oviductal physiology and on contraceptive development.

Richard H. Douglas, PhD, is Vice-president for Corporate Development, the Genzyme Corporation, and has served the corporation as Vice-president for Scientific Development and Director for New Product Development. Prior to holding these positions, Dr. Douglas was Manager of Protein Chemistry Research at Genzyme Integrated Genetics, whose Protein Engineering group combined protein chemistry, molecular biology, and molecular modeling for rational drug design to produce novel proprietary therapeutic molecules. Dr. Douglas earned his PhD in biochemistry from the University of California at Berkeley, after which he held a Postdoctoral Research Fellowship at the California Institute of Technology under Dr. Leroy Hood, focusing on immunology, immunochemistry, molecular biology, and protein microsequencing.

Michael J. K. Harper, PhD, ScD, is presently Professor of Obstetrics and Gynecology at Eastern Virginia Medical School. He also served as Professor at the Baylor College of Medicine Center for Reproductive Medicine and Department of Obstetrics and Gynecology, where his research centered on maternal recognition of pregnancy; chemical mediators such as platelet-activating factor (PAF) and leukemia inhibitory factor (LIF). His previous experience as Technical Officer at ICI (now Zeneca) Pharmaceutical involved research on antihormonal agents for contraception and cancer therapy and the discovery of tamoxifen, a widely used antiestrogen. Dr. Harper has consulted for the World Health Organization, U.S. Agency for International Development, National Institute of Child Health and Development, National Science Foundation, and Andrew W. Mellon Foundation. His many publications include Birth Control Technologies: Prospects by the Year 2000.

Donald P. McDonnell, PhD, is Associate Professor of Pharmacology at Duke University Medical Center. He earned his PhD in cell biology from Baylor College of Medicine in 1987. Between 1991 and 1994 he served as Associate Director, then Director and Head of Molecular Biology at Ligand Pharmaceuticals. Dr. McDonnell has received numerous investigator awards, is on the editorial board of Molecular Endocrinology , and referees articles for Endocrinology , Science , Nature , Proceedings of the National Academy of Sciences USA, and several other scientific journals. He holds patents on several screening assays for steroid hormone receptor agonists and antagonists and has published numerous

Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×

articles in scientific journals, most recently on the topic of nuclear hormone receptors as targets for new drug discovery.

David Mowery, PhD, is Professor of Business and Public Policy at the Walter A. Haas School of Business at the University of California, Berkeley. His research deals with the economics of technological innovation and effects of public policies on innovation. He earned his PhD in economics from Stanford University and was a postdoctoral research fellow at the Harvard Business School. In 19871988, Dr. Mowery served as study director for the National Academy of Sciences Panel on Technology and Employment and, in 1988, as a Council on Foreign Relations Internal Affairs Fellow in the Office of the United States Trade Representative. Among Dr. Mowery's publications are Technology and the Pursuit of Economic Growth; Alliance Politics and Economics; Technology and Employment: Innovation and Growth in the U.S. Economy; and International Collaborative Ventures in U.S. Manufacturing.

Judy Norsigian is Codirector of the Boston Women's Health Book Collective and a consultant to the Massachusetts Department of Public Health, the Contraceptive Research and Development program (CONRAD), World Health Organization, and National Institutes of Health. She was on the board of the National Women's Health Network and now serves on the editorial board for the journal Women and Health. In addition to her work at the Health Collective, she has served on numerous advisory boards and committees for the International Childbirth Education Association, the American Public Health Association, the New England Research Institute, the Planned Parenthood League of Massachusetts, and Family Health International. Ms. Norsigian also served on the National Research Council/Institute of Medicine Committee on Contraceptive Development (1987-1990).

Sandra Panem, PhD, is President, Vector Fund Management, prior to which she was Vice-president and Portfolio Manager at Oppenheimer Management Corporation (1992-1994) and Vice-president at Salomon Brothers (1986-1992). She earned her PhD in microbiology at the University of Chicago. Dr. Panem served as Program Officer for the Alfred P. Sloan Foundation (1966-1968), Guest Scholar at The Brookings Institute (1985-1986), Science Advisor at the US Environmental Protection Agency (1983-1985), and Research Associate and Assistant Professor at the University of Chicago (1971-1982). She is a member of the Board of Directors of the National Center for Human Genome Resources and the Board of Governors of the New York Academy of Sciences.

Allan Rosenfield, MD, FACOG (Committee Chair) is Dean of the Columbia University School of Public Health, Joseph R. DeLamar Professor of Public Health, and Professor of Obstetrics and Gynecology. He received his MD from

Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×

Columbia University. Dr. Rosenfield was the Population Council representative and advisor to the Ministry of Public Health in Bangkok, Thailand, and Assistant Director of the Technical Assistance Division at Population Council headquarters in New York City between 1967 and 1975. He has contributed over 100 articles to professional journals and is a Fellow of the American College of Obstetrics and Gynecology, American Public Health Association, and American Fertility Society.

Bennett M. Shapiro, MD, is Executive Vice-president for Worldwide Basic Research, Merck Research Laboratories. He earned his MD at Jefferson Medical College. Before joining Merck, Dr. Shapiro was on the faculty of biochemistry at the University of Washington (1971-1990) and Chairman of the Biochemistry Department (1985-1990). Between 1968 and 1970 he was a visiting scientist at the Institute Pasteur, Paris, and US Public Health Service surgeon and, from 1965 to 1968, research associate at the National Institutes of Health. He is a member of the American Society of Biologists and Chemists, American Society of Cell Biology, and American Society of Development Biology.

Wylie W. Vale, PhD, is Head of the Clayton Foundation Laboratories for Peptide Biology at the Salk Institute and has been Professor at the Institute since 1980 and serves on its Board of Trustees and as Chairman of Faculty. Of his many named lectures and awards, the most recent is the Vincent du Vigneaud Award of the American Peptide Society (1992). Dr. Vale has been President of the Endocrine Society (1992-1993), the NIDDK Council of Scientific Advisors, and Board of Directors of the Laurentian Hormone Conference, and now serves as Vice-president of the International Society for Neuroendocrinology. Dr. Vale was elected to the US National Academy of Sciences in 1992. The most recent of his numerous scientific publications are concerned with corticotropin-releasing factor and activin receptors.

Bai-ge Zhao, PhD, is Director of the Shanghai Institute of Planned Parenthood Research. She earned her PhD at the University of Cambridge, UK. Prior to that she was Director of the WHO Collaborating Center for Research in Human Reproduction and the National Laboratory for Contraceptives and Devices Research (1990-1994) and Deputy Director of the Medical Section of Shanghai Science and Technology Commission (1984-1985). Dr. Zhao was named Outstanding Woman and Scientist in Shanghai and Outstanding Postgraduate in China. Her basic research in mechanisms of hormone action, signal transduction, and gene expression in aspects of reproductive process, as well as her work with RU 486 and implant technologies, earned her the National Prize for Progress in Science and Technology. She is a member of the New York Academy of Sciences.

Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×
Page 490
Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×
Page 491
Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×
Page 492
Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×
Page 493
Suggested Citation:"Appendix F: Committee Biographies." Institute of Medicine. 1996. Contraceptive Research and Development: Looking to the Future. Washington, DC: The National Academies Press. doi: 10.17226/5156.
×
Page 494
Next: Glossary »
Contraceptive Research and Development: Looking to the Future Get This Book
×
Buy Hardback | $75.00 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The "contraceptive revolution" of the 1960s and 1970s introduced totally new contraceptive options and launched an era of research and product development. Yet by the late 1980s, conditions had changed and improvements in contraceptive products, while very important in relation to improved oral contraceptives, IUDs, implants, and injectables, had become primarily incremental. Is it time for a second contraceptive revolution and how might it happen?

Contraceptive Research and Development explores the frontiers of science where the contraceptives of the future are likely to be found and lays out criteria for deciding where to make the next R&D investments.

The book comprehensively examines today's contraceptive needs, identifies "niches" in those needs that seem most readily translatable into market terms, and scrutinizes issues that shape the market: method side effects and contraceptive failure, the challenge of HIV/AIDS and other sexually transmitted diseases, and the implications of the "women's agenda."

Contraceptive Research and Development analyzes the response of the pharmaceutical industry to current dynamics in regulation, liability, public opinion, and the economics of the health sector and offers an integrated set of recommendations for public- and private-sector action to meet a whole new generation of demand.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!